JP2012507270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507270A5 JP2012507270A5 JP2011533718A JP2011533718A JP2012507270A5 JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5 JP 2011533718 A JP2011533718 A JP 2011533718A JP 2011533718 A JP2011533718 A JP 2011533718A JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5
- Authority
- JP
- Japan
- Prior art keywords
- rad35
- bioreactor
- cells
- perfusion system
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 7
- 230000010412 perfusion Effects 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 241000701124 Human adenovirus 35 Species 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19812208P | 2008-11-03 | 2008-11-03 | |
| EP08168181.9 | 2008-11-03 | ||
| EP08168181 | 2008-11-03 | ||
| US61/198,122 | 2008-11-03 | ||
| PCT/EP2009/064265 WO2010060719A1 (en) | 2008-11-03 | 2009-10-29 | Method for the production of adenoviral vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507270A JP2012507270A (ja) | 2012-03-29 |
| JP2012507270A5 true JP2012507270A5 (enExample) | 2012-12-13 |
| JP5770633B2 JP5770633B2 (ja) | 2015-08-26 |
Family
ID=40344776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533718A Expired - Fee Related JP5770633B2 (ja) | 2008-11-03 | 2009-10-29 | アデノウイルスベクターの産生方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10041049B2 (enExample) |
| EP (1) | EP2350268B1 (enExample) |
| JP (1) | JP5770633B2 (enExample) |
| KR (1) | KR101504392B1 (enExample) |
| CN (1) | CN102203242B (enExample) |
| AU (1) | AU2009319254B2 (enExample) |
| BR (1) | BRPI0921651A2 (enExample) |
| CA (1) | CA2742474C (enExample) |
| DK (1) | DK2350268T3 (enExample) |
| EA (1) | EA019928B1 (enExample) |
| ES (1) | ES2532015T3 (enExample) |
| MX (1) | MX2011004292A (enExample) |
| NZ (1) | NZ593235A (enExample) |
| PL (1) | PL2350268T3 (enExample) |
| WO (1) | WO2010060719A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2350268T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
| AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
| WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| JP5250155B2 (ja) * | 2010-02-15 | 2013-07-31 | クルセル ホランド ベー ヴェー | Ａｄ２６アデノウイルスベクターの製造方法 |
| CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
| CN103347595B (zh) | 2011-02-10 | 2016-01-20 | 克鲁塞尔荷兰公司 | 气动交变压力膜细胞分离系统 |
| WO2013074501A1 (en) | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| AU2013237429B2 (en) | 2012-03-22 | 2015-07-23 | Crucell Holland B.V. | Vaccine against RSV |
| SI2988780T1 (sl) | 2013-04-25 | 2019-05-31 | Janssen Vaccines & Prevention B.V. | Stabilizirani topni prefuzijski RSV F polipeptidi |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| ES2778928T3 (es) * | 2013-08-30 | 2020-08-12 | Glaxosmithkline Biologicals Sa | Producción a gran escala de virus en cultivos celulares |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| BR112017009177A2 (pt) | 2014-11-04 | 2018-12-11 | Janssen Vaccines & Prevention B.V. | vacinas terapêuticas contra hpv16 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| DK3319633T3 (da) | 2015-07-07 | 2021-02-01 | Janssen Vaccines & Prevention Bv | Vaccine mod rsv |
| US9663766B2 (en) | 2015-07-24 | 2017-05-30 | Bio-Rad Laboratories, Inc. | Methods for purifying adenovirus vectors |
| SG10202001501QA (en) | 2015-08-20 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Therapeutic hpv18 vaccines |
| MA43763B1 (fr) | 2016-04-05 | 2021-03-31 | Janssen Vaccines & Prevention Bv | Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs |
| MX2018012095A (es) | 2016-04-05 | 2019-01-10 | Janssen Vaccines & Prevention Bv | Vacuna contra vrs. |
| US10358626B2 (en) * | 2016-04-12 | 2019-07-23 | Artemis Biosystems, Inc. | Perfusion filtration systems |
| EP3452087A1 (en) | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| JP2019523644A (ja) | 2016-05-30 | 2019-08-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された融合前ｒｓｖ ｆタンパク質 |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｐｖワクチン |
| JP7393945B2 (ja) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | 細胞増殖 |
| JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物 |
| US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| SG11202003290RA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
| AU2018359492B2 (en) | 2017-10-31 | 2023-12-14 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| SG11202003398SA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof |
| TWI827570B (zh) * | 2017-12-11 | 2024-01-01 | 美商安進公司 | 雙特異性抗體產品之連續製造製程 |
| CN110317832B (zh) * | 2018-03-28 | 2022-07-05 | 西比曼生物科技（香港）有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
| CN110317791A (zh) | 2018-03-29 | 2019-10-11 | 西比曼生物科技（香港）有限公司 | Gmp级无血清悬浮细胞大规模生产慢病毒的方法 |
| WO2019209632A1 (en) | 2018-04-24 | 2019-10-31 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| CR20210306A (es) | 2018-11-13 | 2021-07-22 | Janssen Vaccines & Prevention Bv | Proteínas f de prefusión del vrs estabilizadas |
| MX2022000002A (es) * | 2019-07-01 | 2022-03-17 | Ology Bioservices Inc | Método para cultivo de células adherentes en un biorreactor multiparalelo. |
| EP4097122A4 (en) | 2020-01-31 | 2024-07-17 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES |
| GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
| AU2021358957A1 (en) | 2020-10-07 | 2023-06-08 | AskBio Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| EP4590689A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| CN120344553A (zh) | 2022-10-06 | 2025-07-18 | Msd国际商务股份有限公司 | 稳定的融合前piv3 f蛋白 |
| WO2024190895A1 (ja) | 2023-03-15 | 2024-09-19 | 東レ株式会社 | フィルターユニット、精製装置及び精製液の製造方法 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04241381A (ja) | 1991-01-16 | 1992-08-28 | Brother Ind Ltd | 電子学習機 |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびａａｖの精製 |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| US6485958B2 (en) | 1996-07-01 | 2002-11-26 | Gencell Sa | Method for producing recombinant adenovirus |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| JP2000509614A (ja) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | アデノウイルスｅ１−相補性細胞系 |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| PL197747B1 (pl) | 1998-02-17 | 2008-04-30 | Schering Corp | Kompozycja zawierająca adenowirusa, sposoby zatężania preparatu wirusa oraz sposób oczyszczania preparatu wirusa |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| BR9909789A (pt) | 1998-04-22 | 2000-12-26 | Genvec Inc | Método de purificação eficiente de adenovìrus |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20040043489A1 (en) | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
| DK1133316T3 (da) | 1998-11-16 | 2009-05-25 | Introgen Therapeutics Inc | Adenovirus-formulering til genterapi |
| CA2356373A1 (fr) | 1998-12-31 | 2000-07-13 | Aventis Pharma S.A. | Methode de separation de particules virales |
| AU774437B2 (en) | 1999-02-22 | 2004-06-24 | Transgene S.A. | Method for obtaining a purified viral preparation |
| ES2289426T3 (es) | 1999-05-17 | 2008-02-01 | Crucell Holland B.V. | Adenovirus recombinante humano de serotipo 35. |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| WO2001066137A1 (en) | 2000-03-07 | 2001-09-13 | Merck & Co., Inc. | Adenovirus formulations |
| US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
| CA2469491A1 (en) | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
| JP4488290B2 (ja) | 2002-01-24 | 2010-06-23 | ザ・スクリップス・リサーチ・インスティテュート | 効率的ターゲティングのためのファイバーシャフト変異 |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| ATE494362T1 (de) | 2002-05-14 | 2011-01-15 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
| AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| CA2507915C (en) | 2002-12-17 | 2013-07-02 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| JP2007525166A (ja) | 2003-03-28 | 2007-09-06 | ザ・スクリップス・リサーチ・インスティテュート | 樹状細胞に対する感染性が増大したアデノウイルス粒子と、肝細胞に対する感染性が低下した粒子 |
| WO2005033320A1 (en) | 2003-10-02 | 2005-04-14 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
| CA2555412C (en) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
| ES2456015T3 (es) * | 2004-03-05 | 2014-04-21 | Dsm Ip Assets B.V. | Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante |
| US7629167B2 (en) | 2004-06-04 | 2009-12-08 | Xcellerex, Inc. | Disposable bioreactor systems and methods |
| KR101253363B1 (ko) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 개선된 아데노바이러스 벡터 및 그것의 용도 |
| SI1802336T1 (sl) | 2004-10-14 | 2012-01-31 | Crucell Holland Bv | Začetna/obnovitvena cepiva proti malariji |
| EA012037B1 (ru) | 2004-11-16 | 2009-06-30 | Круселл Холланд Б.В. | Поливалентные вакцины, содержащие рекомбинантные вирусные векторы |
| EP1851343A2 (en) | 2005-02-11 | 2007-11-07 | Merck and Co., Inc. | Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby |
| EP1869171B2 (en) | 2005-04-11 | 2015-10-14 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| JP2008541730A (ja) | 2005-05-23 | 2008-11-27 | ヴァクシン インコーポレイテッド | 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法 |
| WO2007010409A2 (en) | 2005-07-22 | 2007-01-25 | Pergo (Europe) Ab | Flooring system including a preglue |
| KR101345936B1 (ko) | 2005-08-15 | 2013-12-31 | 박신 인크. | 비복제성 벡터화된 백신 투여에 의한 조류 면역화 |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| EA200900032A1 (ru) | 2006-07-18 | 2011-02-28 | Глаксосмитклайн Байолоджикалс С.А. | Вакцины против малярии |
| ES2609418T3 (es) | 2007-03-02 | 2017-04-20 | Glaxosmithkline Biologicals Sa | Procedimiento novedoso y composiciones |
| US9109193B2 (en) | 2007-07-30 | 2015-08-18 | Ge Healthcare Bio-Sciences Corp. | Continuous perfusion bioreactor system |
| CN101855371A (zh) | 2007-11-14 | 2010-10-06 | 张惇杰 | 制备用于锂离子电池应用的空气敏感性电极材料的方法和装置 |
| WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
| DK2350268T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
| KR101548790B1 (ko) | 2009-07-16 | 2015-08-31 | 크루셀 홀란드 비.브이. | 백신 제조를 위한 고역가 폴리오바이러스의 제조 |
| WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| US20120315696A1 (en) | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
| JP5250155B2 (ja) | 2010-02-15 | 2013-07-31 | クルセル ホランド ベー ヴェー | Ａｄ２６アデノウイルスベクターの製造方法 |
-
2009
- 2009-10-29 DK DK09744140.6T patent/DK2350268T3/en active
- 2009-10-29 JP JP2011533718A patent/JP5770633B2/ja not_active Expired - Fee Related
- 2009-10-29 WO PCT/EP2009/064265 patent/WO2010060719A1/en not_active Ceased
- 2009-10-29 PL PL09744140T patent/PL2350268T3/pl unknown
- 2009-10-29 US US13/126,978 patent/US10041049B2/en active Active
- 2009-10-29 AU AU2009319254A patent/AU2009319254B2/en not_active Ceased
- 2009-10-29 CA CA2742474A patent/CA2742474C/en active Active
- 2009-10-29 NZ NZ593235A patent/NZ593235A/xx not_active IP Right Cessation
- 2009-10-29 BR BRPI0921651-0A patent/BRPI0921651A2/pt not_active Application Discontinuation
- 2009-10-29 EA EA201170638A patent/EA019928B1/ru not_active IP Right Cessation
- 2009-10-29 ES ES09744140.6T patent/ES2532015T3/es active Active
- 2009-10-29 EP EP09744140.6A patent/EP2350268B1/en active Active
- 2009-10-29 CN CN2009801438951A patent/CN102203242B/zh not_active Expired - Fee Related
- 2009-10-29 KR KR1020117010793A patent/KR101504392B1/ko not_active Expired - Fee Related
- 2009-10-29 MX MX2011004292A patent/MX2011004292A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507270A5 (enExample) | ||
| NZ593235A (en) | Method for the production of recombinant adenovirus serotype 35 | |
| JP2014521353A5 (enExample) | ||
| JP2019516410A5 (enExample) | ||
| CN102762721B (zh) | 用于生产Ad26腺病毒载体的方法 | |
| Feuchtinger et al. | Adenovirus infection after allogeneic stem cell transplantation | |
| JP2011125348A5 (enExample) | ||
| WO2020076820A3 (en) | Compositions and methods for preparing viral vectors | |
| JP2009034115A5 (enExample) | ||
| JP2004501647A5 (enExample) | ||
| JP2005512564A5 (enExample) | ||
| JP2007522814A5 (enExample) | ||
| JP2006230415A5 (enExample) | ||
| CN103732236A (zh) | 用于生产痘苗病毒的方法和组合物 | |
| JP2013515473A5 (enExample) | ||
| CN104812893A (zh) | 高感染滴度的细小病毒的生产方法 | |
| JP2013520977A5 (enExample) | ||
| Duffy et al. | Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56 | |
| Dolnik et al. | Shedding of Ebola virus surface glycoprotein is a mechanism of self-regulation of cellular cytotoxicity and has a direct effect on virus infectivity | |
| JP2013538588A5 (enExample) | ||
| JP2008508899A5 (enExample) | ||
| CN116200348A (zh) | 一种适应Vero细胞的柯萨奇病毒A10型毒株的构建方法及其应用 | |
| CN114107389A (zh) | 表达非洲猪瘟病毒b602l-b646l蛋白的重组腺病毒及构建方法 | |
| CN1552851A (zh) | Sars冠状病毒的假病毒及其制备方法和用途 | |
| CN102533657B (zh) | 一种人41型腺病毒(Ad41)包装细胞株及其应用 |